News
- Author:
- Neil Osterweil
Publish date: June 17, 2018
Big survival gains were reported in patients with relapsed/refractory DLBCL treated with polatuzumab vedotin, bendamustine, and rituximab.
News
- Author:
- Neil Osterweil
Publish date: June 8, 2018
In this phase 2 randomized study, adding exemestane had better efficacy than did single-agent everolimus, but single-agent capecitabine appeared to...
News
- Author:
- Neil Osterweil
Publish date: June 7, 2018
A combination of lorlatinib and avelumab showed good activity and acceptable safety against ALK-positive lung cancer, but no better efficacy than t...
News
- Author:
- Neil Osterweil
Publish date: June 5, 2018
CHICAGO – A randomized study of community oncology centers showed that when oncologists were informed of geriatric assessment results, patient sati...
News
- Author:
- Neil Osterweil
Publish date: June 4, 2018
CHICAGO – For patients with NSCLC expressing PD-L1 on at least 1% of tumor, upfront pembrolizumab significantly prolonged OS with lower toxicities ...
News
- Author:
- Neil Osterweil
Publish date: June 3, 2018
CHICAGO – The combination of talesib/fulvestrant extended PFS by two months, but at a cost of serious toxicities in half of the patients treated wi...
News
- Author:
- Neil Osterweil
Publish date: June 2, 2018
CHICAGO - “The nihilism associated with prostate cancer in African-American men is not supported by this really interesting work.”
Video
- Author:
- Neil Osterweil
Publish date: June 2, 2018
CHICAGO - Dr. Harold Burstein questions whether the PI3K pathway is worth pursuing, despite positive results from SANDPIPER.
Video
- Author:
- Neil Osterweil
Publish date: June 2, 2018
CHICAGO - Dr. Supriya Mohile discusses study results indicating that geriatric assessments improve communication and boost patient satisfaction.
Video
- Author:
- Neil Osterweil
Publish date: June 2, 2018
CHICAGO – Lead study author Dr. Daniel George discusses issues surrounding access to the standard of care for advanced prostate cancer.
News
- Author:
- Neil Osterweil
Publish date: May 21, 2018
Patients with mRCC stratified into favorable- and intermediate-risk categories had better response rates and longer survival than did poor-risk pat...
News
- Author:
- Neil Osterweil
Publish date: May 20, 2018
PITTSBURGH – ‘Liquid biopsy’ of patients with genetically profiled tumors showed potentially actionable somatic mutations and copy number alteratio...
News
- Author:
- Neil Osterweil
Publish date: May 17, 2018
PITTSBURGH – CDC investigators detected a significant increase in pediatric cancers from 2001 through 2014, although the reasons for the rise are u...
News
- Author:
- Neil Osterweil
Publish date: May 17, 2018
PITTSBURGH – Could this CAR T therapy become a viable option against pediatric solid tumors?
News
- Author:
- Neil Osterweil
Publish date: May 11, 2018
PITTSBURGH – With better therapy and supportive care, prospects for children with Down syndrome and standard risk ALL have improved in recent years...
